Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets

John A Rathmacher, John C Fuller Jr, Shawn M Baier, Naji N Abumrad, Hector F Angus, Rick L Sharp, John A Rathmacher, John C Fuller Jr, Shawn M Baier, Naji N Abumrad, Hector F Angus, Rick L Sharp

Abstract

Background: Intracellular concentrations of adenosine-5'-triphosphate (ATP) are many times greater than extracellular concentrations (1-10 mM versus 10-100 nM, respectively) and cellular release of ATP is tightly controlled. Transient rises in extracellular ATP and its metabolite adenosine have important signaling roles; and acting through purinergic receptors, can increase blood flow and oxygenation of tissues; and act as neurotransmitters. Increased blood flow not only increases substrate availability but may also aid in recovery through removal of metabolic waste products allowing muscles to accomplish more work with less fatigue. The objective of the present study was to determine if supplemental ATP would improve muscle torque, power, work, or fatigue during repeated bouts of high intensity resistance exercise.

Methods: Sixteen participants (8 male and 8 female; ages: 21-34 years) were enrolled in a double-blinded, placebo-controlled study using a crossover design. The participants received either supplemental ATP (400 mg/d divided into 2 daily doses) or placebo for 15 d. After an overnight fast, participants underwent strength and fatigue testing, consisting of 3 sets of 50 maximal knee extensions performed on a Biodex® leg dynamometer.

Results: No differences were detected in high peak torque, power, or total work with ATP supplementation; however, low peak torque in set 2 was significantly improved (p < 0.01). Additionally, in set 3, a trend was detected for less torque fatigue with ATP supplementation (p < 0.10).

Conclusions: Supplementation with 400 mg ATP/d for 15 days tended to reduce muscle fatigue and improved a participant's ability to maintain a higher force output at the end of an exhaustive exercise bout.

Figures

Figure 1
Figure 1
Timeline of experimental procedures. Each participant participated in two experimental trials, one for each treatment, separated by at least one week for supplement wash out and recovery. During each trial participants were assigned to either: (a) 15 days oral ingestion of placebo; or (b) 15 days oral ingestion of 400 mg ATP/d with the dosage divided into two equal dosages, one in the morning and the other in the evening.
Figure 2
Figure 2
High Peak Torque (A); Low Peak Torque (B) and Torque Fatigue (C) over 3 successive sets of 50-contraction knee extensions in Placebo - - ♦- - and 400 mg ATP/d —▪— supplemented participants. Treatment with ATP approached an overall treatment main effect over placebo supplementation for Low Peak Torque and Torque Fatigue (B and C, † p < 0.11). ATP supplementation resulted in a significant improvement in Set 2 Low Peak Torque (B, * p < 0.01) and a trend for less Torque Fatigue in Set 3 (C, # p < 0.10).

References

    1. Kushmerick MJ, Conley KE. Energetics of muscle contraction: the whole is less than the sum of its parts. Biochem Soc Trans. 2002;30:227–231.
    1. Burnstock G, Knight GE, Greig AV. Purinergic signaling in healthy and diseased skin. J Invest Dermatol. 2012;132:526–546. doi: 10.1038/jid.2011.344.
    1. Agteresch HJ, Dagnelie PC, van den Berg JW, Wilson JH. Adenosine triphosphate: established and potential clinical applications. Drugs. 1999;58:211–232.
    1. Sawynok J, Sweeney MI. The role of purines in nociception. Neuroscience. 1989;32:557–569. doi: 10.1016/0306-4522(89)90278-9.
    1. Yajima H, Sato J, Giron R, Nakamura R, Mizumura K. Inhibitory, facilitatory, and excitatory effects of ATP and purinergic receptor agonists on the activity of rat cutaneous nociceptors in vitro. Neurosci Res. 2005;51:405–416. doi: 10.1016/j.neures.2004.12.008.
    1. Khakh BS, Henderson G. ATP receptor-mediated enhancement of fast excitatory neurotransmitter release in the brain. Mol Pharmacol. 1998;54:372–378.
    1. Hochachka PW, Bianconcini MS, Parkhouse WS, Dobson GP. On the role of actomyosin ATPases in regulation of ATP turnover rates during intense exercise. Proc Natl Acad Sci U S A. 1991;88:5764–5768. doi: 10.1073/pnas.88.13.5764.
    1. Gorman MW, Feigl EO, Buffington CW. Human plasma ATP concentration. Clin Chem. 2007;53:318–325.
    1. Mortensen SP, Thaning P, Nyberg M, Saltin B, Hellsten Y. Local release of ATP into the arterial inflow and venous drainage of human skeletal muscle: insight from ATP determination with the intravascular microdialysis technique. J Physiol. 2011;589:1847–1857. doi: 10.1113/jphysiol.2010.203034.
    1. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783:673–694. doi: 10.1016/j.bbamcr.2008.01.024.
    1. Kichenin K, Seman M. Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. J Pharmacol Exp Ther. 2000;294:126–133.
    1. Heinonen I, Kemppainen J, Kaskinoro K, Peltonen JE, Sipila HT, Nuutila P, Knuuti J, Boushel R, Kalliokoski KK. Effects of adenosine, exercise, and moderate acute hypoxia on energy substrate utilization of human skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2012;302:R385–R390. doi: 10.1152/ajpregu.00245.2011.
    1. Ellis CG, Milkovich S, Goldman D. What is the efficiency of ATP signaling from erythrocytes to regulate distribution of O(2) supply within the microvasculature? Microcirculation. 2012;19:440–450. doi: 10.1111/j.1549-8719.2012.00196.x.
    1. Radegran G, Calbet JA. Role of adenosine in exercise-induced human skeletal muscle vasodilatation. Acta Physiol Scand. 2001;171:177–185. doi: 10.1046/j.1365-201x.2001.00796.x.
    1. Nyberg M, Mortensen SP, Thaning P, Saltin B, Hellsten Y. Interstitial and plasma adenosine stimulate nitric oxide and prostacyclin formation in human skeletal muscle. Hypertension. 2010;56:1102–1108. doi: 10.1161/HYPERTENSIONAHA.110.161521.
    1. Kunugi S, Iwabuchi S, Matsuyama D, Okajima T, Kawahara K. Negative-feedback regulation of ATP release: ATP release from cardiomyocytes is strictly regulated during ischemia. Biochem Biophys Res Commun. 2011;416:409–415. doi: 10.1016/j.bbrc.2011.11.068.
    1. Arts IC, Coolen EJ, Bours MJ, Huyghebaert N, Stuart MA, Bast A, Dagnelie PC. Adenosine 5' -triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebocontrolled cross-over trial in healthy humans. J Int Soc Sports Nutr. 2012;9:16. doi: 10.1186/1550-2783-9-16.
    1. Coolen EJ, Arts IC, Bekers O, Vervaet C, Bast A, Dagnelie PC. Oral bioavailability of ATP after prolonged administration. Br J Nutr. 2011;105:357–366. doi: 10.1017/S0007114510003570.
    1. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993–1002.
    1. Calbet JA, Lundby C, Sander M, Robach P, Saltin B, Boushel R. Effects of ATP-induced leg vasodilation on VO2 peak and leg O2 extraction during maximal exercise in humans. Am J Physiol Regul Integr Comp Physiol. 2006;291:R447–R453. doi: 10.1152/ajpregu.00746.2005.
    1. Jordan AN, Jurca R, Abraham EH, Salikhova A, Mann JK, Morss GM, Church TS, Lucia A, Earnest CP. Effects of oral ATP supplementation on anaerobic power and muscular strength. Med Sci Sports Exerc. 2004;36:983–990. doi: 10.1249/01.MSS.0000128198.97260.8B.
    1. Bangsbo J, Krustrup P, Gonzalez-Alonso J, Saltin B. ATP production and efficiency of human skeletal muscle during intense exercise: effect of previous exercise. Am J Physiol Endocrinol Metab. 2001;280:E956–E964.
    1. Juel C. Lactate-proton cotransport in skeletal muscle. Physiol Rev. 1997;77:321–358.
    1. Conley KE, Kemper WF, Crowther GJ. Limits to sustainable muscle performance: interaction between glycolysis and oxidative phosphorylation. J Exp Biol. 2001;204:3189–3194.
    1. Sprague RS, Bowles EA, Achilleus D, Ellsworth ML. Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle. Acta Physiol (Oxf) 2011;202:285–292. doi: 10.1111/j.1748-1716.2010.02182.x.
    1. Gonzalez-Alonso J, Olsen DB, Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. Circ Res. 2002;91:1046–1055. doi: 10.1161/01.RES.0000044939.73286.E2.
    1. Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, Valat JP. A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back pain. J Rheumatol. 2005;32:1114–1117.
    1. Rossignol M, Allaert FA, Rozenberg S, Valat JP, Avouac B, Peres G, Le Teuff G, Bannwarth B. Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial. Pharmacoepidemiol Drug Saf. 2005;14:861–867. doi: 10.1002/pds.1114.
    1. Swennen EL, Coolen EJ, Arts IC, Bast A, Dagnelie PC. Time-dependent effects of ATP and its degradation products on inflammatory markers in human blood ex vivo. Immunobiology. 2008;213:389–397. doi: 10.1016/j.imbio.2007.10.007.
    1. Gergs U, Boknik P, Schmitz W, Simm A, Silber RE, Neumann J. A positive inotropic effect of adenosine in cardiac preparations of right atria from diseased human hearts. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:533–540. doi: 10.1007/s00210-008-0374-8.
    1. Gergs U, Boknik P, Schmitz W, Simm A, Silber RE, Neumann J. A positive inotropic effect of ATP in the human cardiac atrium. Am J Physiol Heart Circ Physiol. 2008;294:H1716–H1723. doi: 10.1152/ajpheart.00945.2007.
    1. Kichenin K, Decollogne S, Angignard J, Seman M. Cardiovascular and pulmonary response to oral administration of ATP in rabbits. J Appl Physiol. 2000;88:1962–1968. doi: 10.1063/1.1305828.
    1. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235:747–754.
    1. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr. 1991;54:1129S–1134S.
    1. May C, Weigl L, Karel A, Hohenegger M. Extracellular ATP activates ERK1/ERK2 via a metabotropic P2Y1 receptor in a Ca2+ independent manner in differentiated human skeletal muscle cells. Biochem Pharmacol. 2006;71:1497–1509. doi: 10.1016/j.bcp.2006.02.003.

Source: PubMed

3
Předplatit